Browsing by author "Melcher, Alan"
Now showing items 1-20 of 64
-
A blood transcriptome-based analysis of disease progression, immune regulation, and symptoms in coronavirus-infected patients.
Sadanandam, A; Bopp, T; Dixit, S; Knapp, DJHF; Emperumal, CP; et al. (SPRINGERNATURE, 2020-12-08)COVID-19 patients show heterogeneity in clinical presentation and outcomes that makes pandemic control and strategy difficult; optimizing management requires a systems biology approach of understanding the disease. Here ... -
A phase-I trial of pre-operative, margin intensive, stereotactic body radiation therapy for pancreatic cancer: the 'SPARC' trial protocol.
Holyoake, DLP; Ward, E; Grose, D; McIntosh, D; Sebag-Montefiore, D; et al. (BIOMED CENTRAL LTD, 2016-09-13)BACKGROUND: Standard therapy for borderline-resectable pancreatic cancer in the UK is surgery with adjuvant chemotherapy, but rates of resection with clear margins are unsatisfactory and overall survival remains poor. ... -
Anti-PD-1/anti-CTLA-4 efficacy in melanoma brain metastases depends on extracranial disease and augmentation of CD8+ T cell trafficking.
Taggart, D; Andreou, T; Scott, KJ; Williams, J; Rippaus, N; et al. (NATL ACAD SCIENCES, 2018-02-13)Inhibition of immune checkpoints programmed death 1 (PD-1) and cytotoxic T lymphocyte-associated protein 4 (CTLA-4) on T cells results in durable antitumor activity in melanoma patients. Despite high frequency of melanoma ... -
Antibody-Neutralized Reovirus Is Effective in Oncolytic Virotherapy.
Berkeley, RA; Steele, LP; Mulder, AA; van den Wollenberg, DJM; Kottke, TJ; et al. (AMER ASSOC CANCER RESEARCH, 2018-10-01)Immunotherapy is showing promise for otherwise incurable cancers. Oncolytic viruses (OVs), developed as direct cytotoxic agents, mediate their antitumor effects via activation of the immune system. However, OVs also stimulate ... -
Antiviral antibody responses to systemic administration of an oncolytic RNA virus: the impact of standard concomitant anticancer chemotherapies.
Roulstone, V; Mansfield, D; Harris, RJ; Twigger, K; White, C; et al. (BMJ PUBLISHING GROUP, 2021-01-01)BACKGROUND: Oncolytic reovirus therapy for cancer induces a typical antiviral response to this RNA virus, including neutralizing antibodies. Concomitant treatment with cytotoxic chemotherapies has been hypothesized to ... -
APOBEC and Cancer Viroimmunotherapy: Thinking the Unthinkable.
Vile, RG; Melcher, A; Pandha, H; Harrington, KJ; Pulido, JS (AMER ASSOC CANCER RESEARCH, 2021-06-15)The apolipoprotein B mRNA editing enzyme catalytic polypeptide (APOBEC) family protects against infection by degrading incoming viral genomes through cytosine deamination. Here, we review how the potential to unleash these ... -
APOBEC3 Mediates Resistance to Oncolytic Viral Therapy.
Huff, AL; Wongthida, P; Kottke, T; Thompson, JM; Driscoll, CB; et al. (CELL PRESS, 2018-12-21)Tumor cells frequently evade applied therapies through the accumulation of genomic mutations and rapid evolution. In the case of oncolytic virotherapy, understanding the mechanisms by which cancer cells develop resistance ... -
APOBEC3B-mediated corruption of the tumor cell immunopeptidome induces heteroclitic neoepitopes for cancer immunotherapy.
Driscoll, CB; Schuelke, MR; Kottke, T; Thompson, JM; Wongthida, P; et al. (NATURE PUBLISHING GROUP, 2020-02-07)APOBEC3B, an anti-viral cytidine deaminase which induces DNA mutations, has been implicated as a mediator of cancer evolution and therapeutic resistance. Mutational plasticity also drives generation of neoepitopes, which ... -
ATR Inhibition Potentiates the Radiation-induced Inflammatory Tumor Microenvironment.
Dillon, MT; Bergerhoff, KF; Pedersen, M; Whittock, H; Crespo-Rodriguez, E; et al. (AMER ASSOC CANCER RESEARCH, 2019-06-01)PURPOSE: ATR inhibitors (ATRi) are in early phase clinical trials and have been shown to sensitize to chemotherapy and radiotherapy preclinically. Limited data have been published about the effect of these drugs on the ... -
CD4 T cell dynamics shape the immune response to combination oncolytic herpes virus and BRAF inhibitor therapy for melanoma.
Bozhanova, G; Hassan, J; Appleton, L; Jennings, V; Foo, S; et al. (BMJ PUBLISHING GROUP, 2022-03-01)BACKGROUND: Combination herpes simplex virus (HSV) oncolytic virotherapy and BRAF inhibitors (BRAFi) represent promising immunogenic treatments for BRAF mutant melanoma, but an improved understanding of the immunobiology ... -
CEA expression heterogeneity and plasticity confer resistance to the CEA-targeting bispecific immunotherapy antibody cibisatamab (CEA-TCB) in patient-derived colorectal cancer organoids.
Gonzalez-Exposito, R; Semiannikova, M; Griffiths, B; Khan, K; Barber, LJ; et al. (BMJ PUBLISHING GROUP, 2019-03-21)BACKGROUND: The T cell bispecific antibody cibisatamab (CEA-TCB) binds Carcino-Embryonic Antigen (CEA) on cancer cells and CD3 on T cells, which triggers T cell killing of cancer cell lines expressing moderate to high ... -
Combination therapy with oncolytic viruses and immune checkpoint inhibitors.
Chiu, M; Armstrong, EJL; Jennings, V; Foo, S; Crespo-Rodriguez, E; et al. (TAYLOR & FRANCIS LTD, 2020-06-02)Introduction: Immune checkpoint inhibitors (ICI) have dramatically improved the outcome for cancer patients across multiple tumor types. However the response rates to ICI monotherapy remain relatively low, in part due to ... -
Combination Therapy With Reovirus and Anti-PD-1 Blockade Controls Tumor Growth Through Innate and Adaptive Immune Responses.
Rajani, K; Parrish, C; Kottke, T; Thompson, J; Zaidi, S; et al. (CELL PRESS, 2016-01-01)Oncolytic reovirus can be delivered both systemically and intratumorally, in both preclinical models and in early phase clinical trials. Reovirus has direct oncolytic activity against a variety of tumor types and antitumor ... -
Combining BRAF inhibition with oncolytic herpes simplex virus enhances the immune-mediated antitumor therapy of BRAF-mutant thyroid cancer.
Crespo-Rodriguez, E; Bergerhoff, K; Bozhanova, G; Foo, S; Patin, EC; et al. (BMJ PUBLISHING GROUP, 2020-01-01)BACKGROUND: The aggressive clinical behavior of poorly differentiated and anaplastic thyroid cancers (PDTC and ATC) has proven challenging to treat, and survival beyond a few months from diagnosis is rare. Although 30%-60% ... -
Comprehensive characterization of immune landscape of Indian and Western triple negative breast cancers.
Korlimarla, A; Ps, H; Prabhu, J; Ragulan, C; Patil, Y; et al. (ELSEVIER SCIENCE INC, 2022-11-01)PURPOSE: Triple-negative breast cancer (TNBC) is a heterogeneous disease with a significant challenge to effectively manage in the clinic worldwide. Immunotherapy may be beneficial to TNBC patients if responders can be ... -
Computational Image Analysis of T-Cell Infiltrates in Resectable Gastric Cancer: Association with Survival and Molecular Subtypes.
Challoner, BR; von Loga, K; Woolston, A; Griffiths, B; Sivamanoharan, N; et al. (OXFORD UNIV PRESS INC, 2021-01-04)BACKGROUND: Gastric and gastro-esophageal junction cancers (GCs) frequently recur after resection, but markers to predict recurrence risk are missing. T-cell infiltrates have been validated as prognostic markers in other ... -
Consensus guidelines for the definition, detection and interpretation of immunogenic cell death.
Galluzzi, L; Vitale, I; Warren, S; Adjemian, S; Agostinis, P; et al. (BMJ PUBLISHING GROUP, 2020-01-01)Cells succumbing to stress via regulated cell death (RCD) can initiate an adaptive immune response associated with immunological memory, provided they display sufficient antigenicity and adjuvanticity. Moreover, multiple ... -
Differential and longitudinal immune gene patterns associated with reprogrammed microenvironment and viral mimicry in response to neoadjuvant radiotherapy in rectal cancer.
Wilkins, A; Fontana, E; Nyamundanda, G; Ragulan, C; Patil, Y; et al. (BMJ PUBLISHING GROUP, 2021-03-01)BACKGROUND: Rectal cancers show a highly varied response to neoadjuvant radiotherapy/chemoradiation (RT/CRT) and the impact of the tumor immune microenvironment on this response is poorly understood. Current clinical tumor ... -
DNA-PKcs is required for cGAS/STING-dependent viral DNA sensing in human cells.
Hristova, DB; Oliveira, M; Wagner, E; Melcher, A; Harrington, KJ; et al. (CELL PRESS, 2024-01-19)To mount an efficient interferon response to virus infection, intracellular pattern recognition receptors (PRRs) sense viral nucleic acids and activate anti-viral gene transcription. The mechanisms by which intracellular ... -
Dynamic Changes in the NK-, Neutrophil-, and B-cell Immunophenotypes Relevant in High Metastatic Risk Post Neoadjuvant Chemotherapy-Resistant Early Breast Cancers.
Gazinska, P; Milton, C; Iacovacci, J; Ward, J; Buus, R; et al. (AMER ASSOC CANCER RESEARCH, 2022-10-14)PURPOSE: To identify potential immune targets in post-neoadjuvant chemotherapy (NAC)-resistant triple-negative breast cancer (TNBC) and ER+HER2- breast cancer disease. EXPERIMENTAL DESIGN: Following pathology review, 153 ...